| __timestamp | Intra-Cellular Therapies, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 125883000 |
| Thursday, January 1, 2015 | 139626 | 69036000 |
| Friday, January 1, 2016 | 93831530 | 72700000 |
| Sunday, January 1, 2017 | 79419009 | 105700000 |
| Monday, January 1, 2018 | 368673 | 198700000 |
| Tuesday, January 1, 2019 | 477121 | 117600000 |
| Wednesday, January 1, 2020 | 1895029 | 108100000 |
| Friday, January 1, 2021 | 8034589 | 122500000 |
| Saturday, January 1, 2022 | 20443000 | 146700000 |
| Sunday, January 1, 2023 | 33745000 | 257500000 |
In pursuit of knowledge
In the dynamic world of biopharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for United Therapeutics Corporation and Intra-Cellular Therapies, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently demonstrated a higher cost of revenue, peaking at $258 million in 2023, reflecting its expansive operations. In contrast, Intra-Cellular Therapies showed a more volatile pattern, with a significant increase in 2023, reaching $33 million, a 60% rise from the previous year. This disparity highlights the differing scales and strategies of these companies. While United Therapeutics maintains a steady growth trajectory, Intra-Cellular Therapies is rapidly scaling its operations. Understanding these trends provides valuable insights into the operational efficiencies and strategic priorities of these industry players.
Sanofi vs United Therapeutics Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: United Therapeutics Corporation vs Insmed Incorporated
Cost Insights: Breaking Down United Therapeutics Corporation and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for United Therapeutics Corporation and Bausch Health Companies Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Galapagos NV
Cost of Revenue Trends: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Walgreens Boots Alliance, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Lantheus Holdings, Inc.
Cost Insights: Breaking Down Intra-Cellular Therapies, Inc. and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.